Generic Name and Formulations:
Difenoxin HCl 1mg, atropine sulfate 0.025mg; tabs.
Valeant Pharmaceuticals, Inc
Indications for MOTOFEN:
Adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
Initially 2mg, then 1mg after each loose stool or 1mg every 3–4 hours as needed. Max 8mg/24hrs. Discontinue use if no improvement after 48hrs.
Diarrhea associated with organisms that penetrate the intestinal mucosa (eg, toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous colitis associated with broad spectrum antibiotics. Children <2yrs old. Jaundice.
Monitor fluid and electrolyte balance. Withhold dose if severe dehydration or electrolyte imbalance occurs. Acute ulcerative colitis; discontinue if abdominal distention occurs or if other untoward symptoms develop. Advanced hepatorenal disease or abnormal liver function tests; hepatic coma may be precipitated. Children with Down's syndrome. Pregnancy (Cat.C). Nursing mothers: not recommended.
Avoid in patients in whom anticholinergic drugs are contraindicated. Hypertensive crisis possible with concomitant MAOIs. May potentiate barbiturates, tranquilizers, narcotics, alcohol; monitor.
Opioid + anticholinergic.
GI upset, dry mouth, epigastric distress, constipation, dizziness, drowsiness, headache, tiredness, nervousness, insomnia, confusion.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Predicting Seizure Risk Following Ischemic Stroke With SeLECT Score
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Exome-Targeted Capture Sequencing Can Diagnose Previously-Undetected Ataxia
- Strategies for Preventing and Treating Delirium
- High Total Cholesterol Neuroprotective Against Cognitive Decline